Cocrystal Pharma (NASDAQ:COCP) Shares Down 5.6% – Time to Sell?

Cocrystal Pharma, Inc. (NASDAQ:COCP)’s stock price was down 5.6% on Wednesday. The stock traded as low as $1.01 and last traded at $1.01. 22,815 shares traded hands during trading, a decline of 35% from the average daily volume of 35,181 shares. The stock had previously closed at $1.07.

Wall Street Analysts Forecast Growth

COCP has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating on shares of Cocrystal Pharma in a report on Friday, October 9th. Weiss Ratings cut shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold”.

Cocrystal Pharma Stock Performance

The firm has a market capitalization of $20.03 million, a price-to-earnings ratio of -1.37 and a beta of 1.60. The company has a 50 day moving average price of $1.09 and a two-hundred day moving average price of $1.10.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The business had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.10 million. On average, equities analysts expect that Cocrystal Pharma, Inc. will post -0.69 earnings per share for the current fiscal year.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics. The company uses structure-based drug discovery and advanced medicinal chemistry to design small-molecule treatments intended to target viral replication mechanisms.

Cocrystal’s research and development programs have focused primarily on infectious diseases, including influenza A and norovirus. Its pipeline has included orally administered antiviral candidates designed to inhibit viral polymerase proteins, as well as programs addressing other significant viral pathogens.